RET Fusion+ mNSCLC


Updated data in RET fusion+ metastatic non–ؘsmall-cell lung cancer and insights on approaching testing for RET fusions.

Data from the following clinical trials are discussed:

  • Selpercatinib (LOXO-292) in patients with RET-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

  • Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

  • Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced RET fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)

Related Videos
Eric Vallieres, MD, FRCSC
Benjamin Levy, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Saad J. Kenderian, MB, CHB
Jaime Schneider, MD, PhD
Benjamin Creelan, MD
Neel P. Chudgar, MD